ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Seattle, WA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Seattle, WA, USA:

Study Evaluating SC262 in Subjects with R/r Non-Hodgkin's Lymphoma (VIVID)

SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory bioma...

Enrolling
Large B-cell Lymphoma
Non Hodgkin's Lymphoma
Drug: SC262

Phase 1

Sana Biotechnology

Seattle, Washington, United States and 1 other location

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Seattle, Washington, United States and 33 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Seattle, Washington, United States and 55 other locations

and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did no...

Active, not recruiting
Recurrent Central Nervous System Lymphoma
Refractory Small Lymphocytic Lymphoma
Procedure: Leukapheresis
Drug: Cyclophosphamide

Phase 1, Phase 2

Fred Hutchinson Cancer Center (FHCC)
Fred Hutchinson Cancer Center (FHCC)

Seattle, Washington, United States

Locations recently updated

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 2

Genmab
Genmab

Seattle, Washington, United States and 74 other locations

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide

Phase 2

Gilead Sciences
Gilead Sciences

Seattle, Washington, United States of America and 18 other locations

Locations recently updated

targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seattle, Washington, United States and 21 other locations

and obinutuzumab for the treatment of patients with indolent B-cell non-Hodgkin lymphoma. Mosunetuzumab and obinutuzumab a...

Enrolling
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Grade 2 Follicular Lymphoma
Biological: Mosunetuzumab
Procedure: Bone Marrow Biopsy

Phase 2

University of Washington
University of Washington

Seattle, Washington, United States

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

Seattle, Washington, United States of America and 28 other locations

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK...

Enrolling
Non-Hodgkin's Lymphoma
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Seattle, Washington, United States and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems